Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Distal embolization (DE) of atherothrombotic debris into the coronary microcirculation occurs both in stable and unstable coronary syndromes. Despite the well recognized clinical significance of periprocedural myocardial infarction (MI) in stable percutaneous coronary intervention (PCI), the impact of DE has a much higher prognostic impact in the acute setting, and especially in ST-elevation myocardial infarction, where DE is a main determinant of no-reflow phenomenon. The present review aims to describe the pathophysiology of DE and to summarize the currently available pharmacological strategies to prevent and treat DE in the setting of MI, especially focusing on antithrombotic, antiinflammatory and vasodilator agents.

Type

Journal article

Journal

Curr Vasc Pharmacol

Publication Date

07/2012

Volume

10

Pages

463 - 467

Keywords

Anti-Inflammatory Agents, Arrhythmias, Cardiac, Coronary Vessels, Embolism, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Microvessels, Myocardial Infarction, Platelet Aggregation Inhibitors, Vasodilator Agents